Organization (Industry)
Emergent BioSolutions Inc.
ClinicalTrials.gov lists Emergent BioSolutions Inc. as lead sponsor of 47 trials. It has 82 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs. 4 trials are registered to start in 2027 or later.
Logo Emergent Biosolutions, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Emergent BioSolutions Inc.: 47 lead-sponsored trials and 5 legal-entity registrations.
Disease areas (39)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anthrax | 14 |
| Smallpox | 7 |
| Cholera | 6 |
| Chikungunya Fever | 4 |
| Vaccinia | 4 |
Showing 5 of 39 disease areas.
Trials by start year as sponsor or collaborator (21)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 4 |
Showing 10 of 21 years.
Recruitment duration, a model prediction: none of the 47 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (82)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| BioThrax | Anthrax | Phase 3 | 5 |
| AV7909 | Anthrax | Phase 3 | 3 |
| HuMax-CD4 | Lymphoma, Non-Hodgkin | Phase 2/3 | 1 |
| HuMax-CD4 | Lymphoma | Phase 2/3 | 1 |
| ACAM2000 Smallpox Vaccine | Smallpox | Phase 2 | 2 |
Showing 5 of 82 active programs.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| AVA | 2 |
| Raxibacumab | 1 |
| Vaccination with ACAM2000 | 1 |
| Sample Collection | 1 |
| Diphenhydramine | 1 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=15) | 60% on time (n=15) |
Journals published in (34)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Vaccine | 11 |
| Clinical and vaccine immunology : CVI | 4 |
| Antimicrobial agents and chemotherapy | 3 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 3 |
| PLoS neglected tropical diseases | 3 |
Showing 5 of 34 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 2014-07-15 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 742,900,000 | 52,600,000 | 53,200,000 |
| 2024 | 1,043,600,000 | -190,600,000 | 70,700,000 |
| 2023 | 1,049,300,000 | -760,500,000 | 111,400,000 |
| 2022 | 1,117,500,000 | -211,600,000 | 188,300,000 |
| 2021 | 1,773,600,000 | 219,500,000 | 235,200,000 |
| 2020 | 1,555,400,000 | 305,100,000 | 234,500,000 |
| 2019 | 1,106,000,000 | 54,500,000 | 226,200,000 |
| 2018 | 782,400,000 | 62,700,000 | 142,800,000 |
| 2017 | 560,900,000 | 82,600,000 | 97,400,000 |
| 2016 | 488,800,000 | 51,800,000 | 106,900,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (64)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-26 | Other financing | 52,700,000 | Sec extracted |
| 2026-04-16 | Debt financing | 150,000,000 | Sec extracted |
| 2026-04-16 | Debt financing | not disclosed | Sec extracted |
| 2025-12-31 | Debt financing | not disclosed | Sec extracted |
| 2025-09-05 | Other financing | not disclosed | Sec extracted |
Showing 5 of 64 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Emergent Biosolutions | Baltimore, US | Health Canada |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (13)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Bavarian Nordic (Denmark) | Co sponsors trial with | 10 |
| Government of the United States of America | Co sponsors trial with | 4 |
| Aeras | Co sponsors trial with | 1 |
| University System of Maryland | Co sponsors trial with | 1 |
| Iqvia Holdings Inc. | Uses vendor | 1 |
Showing 5 of 13 relationships.
Latest dated events (132)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2035-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-05-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 132 events.
Biomarker capability evidence (84)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CLEC3B | Trial sponsor | Primary endpoint in a Phase 3 trial |
| CLEC3B | Trial sponsor | Primary endpoint in a Phase 3 trial |
| CPE | Trial sponsor | Named in trial inclusion criteria |
| CPVL | Trial collaborator | Primary endpoint in a Phase 3 trial |
Showing 5 of 84 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.